Mainstay Medical making progress toward commercialising back pain treatment
The company said Germany is its first target market in Europe for ReActiv8
Mainstay Medical said it continues to make progress toward the commercialisation in Europe of its treatment for chronic back pain, ReActiv8, as it awaits CE marking approval for the treatment.
In its latest financial statement, the company said Germany is its first target market and it has begun preparations, including interacting with medical personnel and recruiting direct sales and support staff.
"In Germany we plan to use a small direct sales force to ...
